Vogt T, Lüssi F, Paul A, Urban P
Neurologische Universitätsklinik, Langenbeckstrasse 1, 55131, Mainz.
Nervenarzt. 2008 Aug;79(8):912-7. doi: 10.1007/s00115-008-2486-2.
Although botulinum neurotoxin A has been used for many years to treat focal dystonia-like blepharospasm (BLSP), cervical dystonia (CD), and hemifacial spasm (HFS) as vascular compression disorder of the facial nerve, there are few data on its long-term efficacy.
We analysed dosages and injection intervals in a group of 130 patients with various focal dystonias treated for 6-16 years.
During the observation period from 2000 to 2006, the mean dosage required to obtain appropriate clinical benefit increased only slightly in BLSP and HSF. In CD however, significantly higher doses were necessary for good clinical results. The mean intervals between injection varied highly between individual patients but did not change significantly between 2000 and 2006. Adverse effects, mostly minor, were reported in 4.2% of all treatment cycles in HSF; the frequencies were 3.8 for BLSP and 2.9 for CD, respectively. None of the patients stopped treatment because of resistance due to antibodies.
Botulinum neurotoxin A is effective in long-term treatment of focal dystonia when injection intervals and dosages are chosen carefully.
尽管多年来肉毒杆菌神经毒素A已被用于治疗局灶性肌张力障碍,如眼睑痉挛(BLSP)、颈部肌张力障碍(CD)和半面痉挛(HFS),这些疾病被视为面神经的血管压迫性疾病,但关于其长期疗效的数据却很少。
我们分析了一组130例接受治疗6至16年的各种局灶性肌张力障碍患者的剂量和注射间隔。
在2000年至2006年的观察期内,在BLSP和HSF中,获得适当临床疗效所需的平均剂量仅略有增加。然而,在CD中,为取得良好的临床效果需要显著更高的剂量。注射间隔的平均值在个体患者之间差异很大,但在2000年至2006年期间没有显著变化。在HSF的所有治疗周期中,有4.2%报告了不良反应,大多为轻微反应;BLSP和CD的不良反应发生率分别为3.8%和2.9%。没有患者因抗体导致的耐药性而停止治疗。
当仔细选择注射间隔和剂量时,肉毒杆菌神经毒素A对局灶性肌张力障碍的长期治疗有效。